How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Viral Vectors Gene Therapy Market
- By Vector Type: Adeno-Associated Virus (AAV) Vectors, Lentiviral Vectors, Adenoviral Vectors, Retroviral Vectors, Herpes Simplex Virus (HSV) Vectors
- By Therapy Area: Oncology, Rare Genetic Disorders, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases
- By Application: Ex Vivo Gene Therapy, In Vivo Gene Therapy
- By End User: Hospitals and Clinics, Research and Academic Institutes, Biopharmaceutical Companies
- By Product Type: Viral Vector Manufacturing Services, Viral Vector Kits and Reagents, Viral Vector Analytical Services
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Adeno-Associated Virus (AAV) Vectors leads By Vector Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Viral Vectors Gene Therapy Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Vector Type 5
Therapy Area 5
Application 2
End User 3
Product Type 3
Companies profiled
Novartis AG
Gilead Sciences
Inc. (Kite Pharma)
Bristol-Myers Squibb Company
Sarepta Therapeutics Inc.
Bluebird Bio Inc.
UniQure N.V.
REGENXBIO Inc.
Audentes Therapeutics (Astellas Pharma)
Homology Medicines Inc.
MeiraGTx Holdings plc
Voyager Therapeutics Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Inc. (Kite Pharma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sarepta Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bluebird Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →UniQure N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →REGENXBIO Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Audentes Therapeutics (Astellas Pharma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Homology Medicines Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →MeiraGTx Holdings plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Voyager Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Dyno Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Freeline Therapeutics Holdings plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Solid Biosciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →AskBio (a subsidiary of Bayer AG)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,051M by 2033 · 7.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Adeno-Associated Virus (AAV) Vectors49.7
- Lentiviral Vectors9.1
- Adenoviral Vectors12.5
- Retroviral Vectors9.0
- Herpes Simplex Virus (HSV) Vectors19.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,655M → $3,220M · 8.7%
Europe$1,154M → $2,279M · 8.9%
Asia Pacific$1,053M → $1,932M · 7.9%
Latin America$652.2M → $1,248M · 8.5%
Middle East and Africa$501.7M → $917.9M · 7.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.602026
7.632027
7.642028
7.642029
7.652030
7.672031
7.672032
7.702033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG22.6
- Gilead Sciences13.5
- Inc. (Kite Pharma)12.4
- Bristol-Myers Squibb Company9.1
- Sarepta Therapeutics Inc.5.0
- Bluebird Bio Inc.9.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vector Type18.7%
Therapy Area11.6%
Application28.3%
End User23.0%
Product Type18.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe23.7
- Asia Pacific20.1
- Latin America13.0
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 96 | 82 | 84 | 79 | 87 | 77 | 84 |
| Gilead Sciences | 89 | 71 | 72 | 83 | 75 | 87 | 80 |
| Inc. (Kite Pharma) | 88 | 69 | 81 | 62 | 68 | 70 | 73 |
| Bristol-Myers Squibb Company | 77 | 58 | 79 | 61 | 72 | 75 | 70 |
| Sarepta Therapeutics Inc. | 71 | 53 | 64 | 54 | 61 | 53 | 59 |
| Bluebird Bio Inc. | 69 | 55 | 62 | 63 | 66 | 52 | 61 |
| UniQure N.V. | 53 | 65 | 57 | 46 | 49 | 50 | 53 |
| REGENXBIO Inc. | 53 | 38 | 49 | 57 | 48 | 59 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Gilead Sciences
- Inc. (Kite Pharma)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Gilead Sciences | ✓ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Inc. (Kite Pharma) | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Bristol-Myers Squibb Company | ◐ | ◐ | ✓ | − | ◐ | ◐ |
| Sarepta Therapeutics Inc. | ◐ | ◐ | ◐ | − | − | ◐ |
| Bluebird Bio Inc. | ✓ | − | ◐ | − | ◐ | − |
| UniQure N.V. | − | − | − | ◐ | − | − |
| REGENXBIO Inc. | − | − | ◐ | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG84
2Gilead Sciences80
3Inc. (Kite Pharma)73
4Bristol-Myers Squibb Company70
5Bluebird Bio Inc.61
6Sarepta Therapeutics Inc.59
7UniQure N.V.53
8REGENXBIO Inc.51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGGilead Sciences
Challenger2
Strong scale, closing on the leaders.
Inc. (Kite Pharma)Bristol-Myers Squibb Company
Contender2
Focused players with pockets of strength.
Sarepta Therapeutics Inc.Bluebird Bio Inc.
Niche2
Specialists in a single segment or region.
UniQure N.V.REGENXBIO Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vector Type in North America, then scale across Viral Vectors Gene Therapy Market — a $118M beachhead inside a $1.99B market.
Beachhead (SOM)$118Mobtainable near-term
Serviceable (SAM)$754Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Adeno-Associated Virus (AAV) Vectors
Best fit — highest urgency & budget in Vector Type.
Economic buyer79 fit
Lentiviral Vectors
Strong fit — clear ROI and a fast path to value.
End user65 fit
Adenoviral Vectors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vector Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapy Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Vector Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Viral Vectors Gene Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified22%
Evaluation12%
Closed-won6%
$12.9KCAC
$62KLTV
4.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Viral Vectors Gene Therapy Market is a durable-growth opportunity — $6.01B by 2033, compounding at 8.1%.
TAM · 2025$3.22Btoday
TAM · 2033$6.01Bforecast
CAGR8.1%2027–2033
Cumulative$40.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.01BTotal addressable market
SAM$2.34BServiceable available market
SOM$414MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.1% CAGR
Demand compounds through 2033, outpacing GDP across Vector Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vector Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.01BLarge & growingTAM by 2033 at 8.1% CAGR
$2.34BServiceable nowreachable with today’s model
$414MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.69BBear5.3% CAGR
$6.01BBase8.1% CAGR
$7.70BBull10.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapy Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Viral Vectors Gene Therapy Market — a $5.70B market by 2033. Plan: grow share from 8.8% to 14.1%.
Market size · 2033$5.70Btotal addressable
Market CAGR5.5%2027–2033
Target share14.1%from 8.8% today
Revenue ambition$804Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 14.1% | Ahead |
| Revenue | $501M | $804M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 34.0% | 41.2% | Behind |
| Customer retention | 88.5% | 93.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vector Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapy Area capability
A defensible second engine — invest in Therapy Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vector Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapy Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $105M capacity & capability investment
- Greenlight bolt-on M&A in Therapy Area
- Authorise North America expansion plan
- Fund R&D program for Vector Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Viral Vectors Gene Therapy Market conversation — a $12.8B market you can size, segment and defend in minutes.
Market size · 2033$12.8Btotal opportunity
Growth11.1%CAGR to 2033
Addressable buyers1,153+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vector Type
Goal Grow share in Vector Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 4 mopayback period
$70K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Novartis AGGilead SciencesInc. (Kite Pharma)Bristol-Myers Squibb CompanySarepta Therapeutics Inc.Bluebird Bio Inc.UniQure N.V.REGENXBIO Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Viral Vectors Gene Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Viral Vectors Gene Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Viral Vector Purification Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportViral Vector Production (Research-use) Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportViral Vector Packaging Services Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportViral Vector Manufacturing Services Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportViral Vector Manufacturing Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportViral Vector CDMO Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportViral Vector-Based Gene Therapy Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportViral Vector and Vaccine Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportViral Vector and Plasmid DNA Testing Service Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportViral Vector and Plasmid DNA Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportViral Vaccine Media Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportViral Vaccine Cell Culture Media Market
Market size, share, segmentation and regional forecast.
$557M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.